Improvement of Depression and Anxiety After Discontinuation of Long- Term Efavirenz Treatment.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  CNS and Neurological Disorders - Drug Targets

• Publication date

  2015-07-31

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.2174/1871527314666150325235847PMID 25808896
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Can antiretroviral therapy prevent HIV-associated cognitive disorders?

  2014cited by this paper
• Cyproheptadine for Prevention of Neuropsychiatric Adverse Effects of Efavirenz: A Randomized Clinical Trial

  2013cited by this paper
• The cognitive consequences of stigma, social withdrawal, and depression in adults aging with HIV.

  2013cited by this paper
• Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects

  2013cited by this paper
• A case-control pilot study on cognitive functioning, symptom validity and psychological wellbeing in HIV-1-infected patients in the Netherlands

  2013cited by this paper
• Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score

  2013cited by this paper
• Validity of the Depression Anxiety Stress Scales in assessing depression and anxiety following traumatic brain injury.

  2013cited by this paper
• Feedback on patient progress and clinical support tools for therapists: improved outcome for patients at risk of treatment failure in psychosomatic in-patient therapy under the conditions of routine practice.

  2013cited by this paper
• Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis

  2013cited by this paper
• Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor.

  2013cited by this paper
• Chinese college students' SCL-90 scores and their relations to the college performance.

  2013cited by this paper
• The HIV Antiretroviral Drug Efavirenz has LSD-Like Properties

  2013cited by this paper
• Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid

  2013cited by this paper
• Measurement of anxious traits: a contemporary review and synthesis

  2012cited by this paper
• Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals

  2012cited by this paper
• Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients

  2011cited by this paper
• A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine

  2011cited by this paper
• A Systematic Review of the Psychiatric Side-Effects of Efavirenz

  2011cited by this paper
• Long-Term Efficacy, Safety, and Tolerability of Rilpivirine (RPV, TMC278) in HIV Type 1-Infected Antiretroviral-Naive Patients: Week 192 Results from a Phase IIb Randomized Trial

  2011cited by this paper
• CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy

  2011cited by this paper
• Prediction of major affective disorders in adolescents by self-report measures.

  2009cited by this paper
• Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.

  2009cited by this paper
• Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097s)

  2009cited by this paper
• The Outcome Questionnaire 45.2. Italian validation of an instrument for the assessment of phychological treatments

  2008cited by this paper
• Meta-analysis of cognitive-behavioral interventions on HIV-positive persons' mental health and immune functioning.

  2008cited by this paper
• Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.

  2006cited by this paper
• Switch from Efavirenz to Nevirapine Associated with Resolution of Efavirenz-Related Neuropsychiatric Adverse Events and Improvement in Lipid Profiles

  2006cited by this paper
• Efavirenz and chronic neuropsychiatric symptoms: a cross‐sectional case control study

  2006cited by this paper
• Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals

  2005cited by this paper
• Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.

  2005cited by this paper
• Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approaches: Quality of Life, Psychologic Issues, and Adherence

  2005cited by this paper
• Efavirenz Induces Depressive-Like Behaviour, Increased Stress Response and Changes in the Immune Response in Rats

  2005cited by this paper
• Evaluating mental health outcomes in an inpatient setting: Convergent and divergent validity of the OQ-45 and BASIS-32

  2002cited by this paper
• Management of sudden psychiatric disorders related to efavirenz.

  2001cited by this paper
• Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

  2001cited by this paper
• The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories.

  1995cited by this paper

• Prevalence of depression among people living with HIV in rural hospitals in South-Western Nigeria-Association with clinico-demographic factors

  2023cites this paper
• The prevalence of depression, anxiety and associated factors among adults with living human immunodeficiency virus in University Malaya Medical Centre

  2022cites this paper
• Substance use, Unlike Dolutegravir, is Associated with Mood Symptoms in People Living with HIV

  2021cites this paper
• Long-term efavirenz exposure induced neuroinflammation and cognitive deficits in C57BL/6 mice.

  2021cites this paper
• CNS Considerations in ART Simplification Strategies

  2021cites this paper
• Treatment non-responsiveness in depression following Efavirenz administration

  2020influential citation
• Suicidal ideation, psychopathology and associated factors among HIV-infected adults in Indonesia

  2020cites this paper
• Efficacy, safety and CNS effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine in a randomized controlled trial.

  2020cites this paper
• Depression is associated with efavirenz-containing treatments in newly antiretroviral therapy initiated HIV patients in Ecuador

  2020cites this paper
• Neuropsychiatric symptoms in Tanzanian HIV-infected children receiving long-term efavirenz treatment: a multicentre, cross-sectional, observational study.

  2019cites this paper
• Neuropsychological changes in efavirenz switch regimens.

  2019cites this paper
• Discontinuation of Efavirenz in Paediatric Patients: Why do Children Switch?

  2018cites this paper
• Efavirenz is related to neuropsychiatric symptoms among adults, but not among adolescents living with human immunodeficiency virus in Kilimanjaro, Tanzania

  2018cites this paper
• Anxiety , depression and sleep disturbances in HIV + patients chronically treated with an efavirenz-based regimen

  2017cites this paper
• Depression and anxiety were low amongst virally suppressed, long-term treated HIV-infected individuals enrolled in a public sector antiretroviral program in Thailand*

  2017cites this paper
• Cognitive assessment, wellbeing and brain functioning in HIV-infected patients on cART

  2017cites this paper
• Stigma kills! The psychological effects of emotional abuse and discrimination towards a patient with HIV in Uganda

  2017cites this paper
• HIV antiretroviral drug Efavirenz induces anxiety‐like and depression‐like behavior in rats: evaluation of neurotransmitter alterations in the striatum

  2017cites this paper
• Prevalence, impact, and management of depression and anxiety in patients with HIV: a review

  2016cites this paper
• Prevalence, impact, and management of depression and anxiety in patients with HIV: a review

  2016cites this paper
• Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen

  2016cites this paper
• Rethinking the risk-benefit ratio of efavirenz in HIV-infected children.

  2016cites this paper
• Short Communication: The Impact of Switching from Atripla to Darunavir/Ritonavir Monotherapy on Neurocognition, Quality of Life, and Sleep: Results from a Randomized Controlled Study.

  2016cites this paper
• Neuropsychiatric Effects of HIV Antiviral Medications

  2016cites this paper
• Cognitive functioning, wellbeing and brain correlates in HIV-1 infected patients on long-term combination antiretroviral therapy

  2015cites this paper
• Eliciting adverse effects data from participants in clinical trials.

  2013cites this paper